Raymond James maintains AbbVie stock Outperform with $218 target
James analyst Gary Nachman maintained an Outperform rating on AbbVie stock (NYSE:ABBV) with a $218.00 price target. The ...
AHF Calls Out Prime Therapeutics’ Lies After $10M PBM Price-fixing Ruling
"Prime demonstrated how actual patients saved on prescription drugs as a result of the agreement [between Prime and Express Scripts, Inc. ('ESI')]. With this ruling, AHF is seeking to rewind the clock ...